Current Cancer Drug Targets

Editor-in-Chief

Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
(USA)

Personal Subscription
Become EABM
Become Reviewer



Meet Our Executive Guest Editor free to download

Volume:20   Issue: 4
Pp: 239-239
C. Xu
DOI: 10.2174/156800962004200430123432
Published on: 30 April, 2020



Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation

Volume:20   Issue: 4
Pp: 240-252
Miriana Cardano, Carla Tribioli and Ennio Prosperi*
DOI: 10.2174/1568009620666200115162814
Published on: 30 April, 2020




Old and New Approaches to Target the Hsp90 Chaperone

Volume:20   Issue: 4
Pp: 253-270
Jackee Sanchez, Trever R. Carter, Mark S. Cohen* and Brian S.J. Blagg
DOI: 10.2174/1568009619666191202101330
Published on: 30 April, 2020




Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications

Volume:20   Issue: 4
Pp: 271-287
Kuldeep Rajpoot*
DOI: 10.2174/1568009620666200115160805
Published on: 30 April, 2020




circEPSTI1 Acts as a ceRNA to Regulate the Progression of Osteosarcoma

Volume:20   Issue: 4
Pp: 288-294
Xinyu Tan, Duxun Tan, Haomiao Li, Ye Lin, Zhishen Wen and Canjun Zeng*
DOI: 10.2174/1568009619666191107140948
Published on: 30 April, 2020




In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors

Volume:20   Issue: 4
Pp: 295-305
Halah Obaid, Sunand Kannappan, Mehul Gupta, Yibing Ruan, Chunfen Zhang, Pinaki Bose* and Aru Narendran*
DOI: 10.2174/1568009619666191111153049
Published on: 30 April, 2020




Disintegrin Tablysin-15 Suppresses Cancer Hallmarks in Melanoma Cells by Blocking FAK/Akt/ERK and NF-κB Signaling

Volume:20   Issue: 4
Pp: 306-315
Zhenhui Deng, Qingye Zeng, Jinwei Chai, Bei Zhang, Wenhong Zheng, Xueqing Xu* and Jiguo Wu*
DOI: 10.2174/1568009620666200101094736
Published on: 30 April, 2020